Table 1.
Demographic and clinical characteristics of patients
| Patients N = 466 | |
|---|---|
| Age (years), mean (SD) | 63.3 (12.89) |
| Sex, male, n (%) | 263 (56.4) |
| ECOG performance status, n (%) | |
| 0–1 | 439 (94.2) |
| 2–4 | 27 (5.8) |
| Body mass index (kg/m2), mean (SD) | 22.5 (3.52) |
| Pathological diagnosis | |
| Diffuse large B-cell lymphoma | 378 (81.1) |
| Follicular lymphoma | 36 (7.7) |
| Transformed diffuse large B-cell lymphoma | 15 (3.2) |
| Other B-cell lymphoma | 37 (7.9) |
| Ann Arbor stage, n (%) | |
| Limited (I–II) | 262 (56.2) |
| Advanced (III–IV) | 204 (43.8) |
| Bone marrow infiltration, n (%) | 44 (9.4) |
| Complications, n (%) | |
| Diabetes | 46 (9.9) |
| Hepatic, renal, or heart disease | 30 (6.4) |
| History of surgery 1 month earlier R-CHOPa | 3 (0.6) |
| Active infection | 15 (3.2) |
| Albumin (g/L), mean (SD) | 38.2 (5.49) |
| Total bilirubin (μmol/L), mean (SD) | 10.3 (5.87) |
| Hemoglobin (g/L), mean (SD) | 124.1 (18.72) |
| Absolute neutrophil count (×109/L), mean (SD) | 4.6 (2.54) |
| Absolute lymphocyte count (×109/L), mean (SD) | 1.5 (1.82) |
| Relative dose intensity (%), mean (SD) | 89.0 (12.41) |
ECOG Eastern Cooperative Oncology Group, FN febrile neutropenia, N number of patients analyzed
aChemotherapeutic regimen comprising rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone